ArticleOncology letters2012
Roles of matrix metalloproteinase-26 in the growth, invasion and angiogenesis of breast cancer.
Article in Oncology letters, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 11 citations in OpenAlex.
- A guide to the types, structures, and multifaceted functions of matrix metalloproteinases in cancer.The FEBS journal · 2026Review
- Plasma Concentrations of Matrilysins (MMP-7, MMP-26) and Stromelysins (MMP-3, MMP-10) as Diagnostic Biomarkers in High-Grade Serous Ovarian Cancer Patients.International journal of molecular sciences · 2025Article
- Nano-Drug Delivery Systems Targeting MMPs: A Promising Treatment for Gliomas.International journal of nanomedicine · 2025Review
- Plasma Concentrations of Matrilysins MMP-7 and MMP-26 as Diagnostic Biomarkers in Breast Cancer.Journal of clinical medicine · 2021Article
- Matrilysins and Stromelysins in Pathogenesis and Diagnostics of Cancers.Cancer management and research · 2020Review
- Identification of the endoplasmic reticulum localization sequence andRSC advances · 2019Article
- High MMP-26 expression in glioma is correlated with poor clinical outcome of patients.Oncology letters · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Matrix metalloproteinase-26 (MMP-26) is a novel member of the MMP family and plays a significant role in the progression of estrogen-dependent malignancies. The present study aimed to investigate the roles of MMP-26 in the growth, invasion and angiogenesis of breast cancer. pcDNA3.1(+)-neo expression plasmids carrying the proMMP-26 coding sequence were used to transfect a breast cancer cell line (MCF-7 cells). The mRNA and protein expression of MMP-26 was determined by RT-PCR, immunofluorescence analysis and flow cytometry. The morphology of transfected cells was observed under an electron microscope. An adherence and spreading assay, Boyden chamber assay, in vivo tumorigenicity assay and in vivo angiogenesis were further modeled to elucidate the roles of MMP-26 in the invasion and angiogenesis of breast cancer. Using electron microscopy, the MMP-26-transfected cells demonstrated increased atypia, including unusual mitotic figures, glucogen pools and special lysosomes in the cytoplasm. The adherence and spreading ability of MMP-26-transfected cells were increased significantly compared with cells in the control group. The Boyden chamber assay demonstrated that the migration and invasion ability of MMP-26-transfected cells was dramatically accelerated compared with the control group, but markedly reduced in the presence of anti-MMP-26 antibody. MMP-26 also increased the malignant phenotype in vivo. The number of vessel branches and the total length of vessels induced by MMP-26-transfected cells were significantly increased compared to those induced by non-transfected cells. The plasmid carrying the proMMP-26 gene was successfully transfected into breast cancer cells. Our results demonstrate that MMP-26 overexpression promotes the growth and invasion of breast cancer cells and induces angiogenesis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.